YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Acadia Pharmaceuticals (ACAD) just stacked two key clinical milestones: a fresh USPTO Notice of Allowance extending potential trofinetide protection to 2041 and Phase 2 RADIANT data guiding remlifanserin into Phase 3 for Alzheimer's diseas…
Acadia Pharmaceuticals ACAD has strengthened the intellectual property protection surrounding trofinetide, marketed in the United States as Daybue, following a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO). The allo…
-- The allowance strengthens the intellectual property portfolio for trofinetide and extends protections in the U.S. from July 2036 to March 2041 SAN DIEGO, September 28, 2026--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) to…
Options bears are circling three stocks today, with Aemetis Inc (NASDAQ:AMTX), Acadia Pharmaceuticals Inc (NASDAQ:ACAD), and Resideo Technologies Inc (NYSE:REZI) all seeing puts handily outpace calls. The bearish activity comes amid mixed…
Acadia Pharmaceuticals has seen its share price fall sharply over the past month, and that pullback is pushing investors to ask whether the current valuation still lines up with what the business is earning today. With the stock under pres…
Acadia Pharmaceuticals ACAD announced phase III-enabling top-line results from the phase II portion of the RADIANT study evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychos…
ACADIA Pharmaceuticals (NASDAQ:ACAD) fell for a fifth consecutive day on Thursday, shedding 12.78 percent to close at $22.18 apiece, after earning a sell recommendation from Goldman Sachs. In its market note, the investment firm reiterated…
Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark in a Phase 2 study. Continue Reading
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
ACADIA Pharmaceuticals' (ACAD) shares dropped 10% pre-bell after it reported that its phase 2 RADIAN PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect -- Narrowly missed primary endpoint of SAPS H+D (…
Company Logo Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough Thera…
It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 0.5% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend cont…
AcadeMedia (OM:ACAD) has drawn fresh attention after reporting its fourth quarter and full year results to June 30, 2026. The sales and net income figures indicate stronger operational performance across the education portfolio. The earnin…
Acadia Pharmaceuticals ACAD announced that the European Commission (EC) has granted marketing authorization for Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and old…
SAN DIEGO, August 24, 2026--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symp…
Neurocrine Biosciences NBIX has had an encouraging start so far in 2026, with strong revenue growth, supported by continued momentum in its commercial portfolio. The top-line benefits primarily from Ingrezza, the company's blockbuster VMAT…
(RTTNews) - The following biotech stocks reached a 52-week high on August 12, 2026, driven up by key catalysts such as positive quarterly reports or promising results from clinical trials. BioVie Inc. (BIVI) BioVie is a clinical-stage biop…
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026, at 4:30 p.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations and Corporate Development - Albert KildaniChief Executive Officer - Catherine Owen AdamsChief Commercial…
Immunic appoints Elena Ridloff to board of directors Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff curr…
Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher cash flow and a strong balance sheet, but upcoming Remlifanserin trial data and the stock's valuation keep the outlook balanced, Morgan Stanl…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. ACADIA Pharmaceuticals has seen its fair value price target adjuste…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Acadia Pharmaceuticals (ACAD) is a stock that can certainly grab the attention of many investors, but do its recent returns…
Acadia Pharmaceuticals (ACAD) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earn…
The Alzheimer's disease market dynamics are anticipated to change due to the expected launch of emerging therapies, such as Masupirdinea (Suven Life Sciences), Trontinemabb (Roche), Buntanetap (Annovis bio), Masitinib (AB Science), Remtern…
With the broader market hovering near record highs, many investors may be looking to healthcare stocks for their historically defensive characteristics, making medical companies that are also delivering standout earnings results especially…
Acadia Pharmaceuticals ACAD reported second-quarter 2026 earnings of 18 cents per share, which surpassed the Zacks Consensus Estimate of 6 cents. The company had reported earnings of 16 cents per share in the year-ago quarter. Revenues of…
This article first appeared on GuruFocus. Total Revenue: $308 million in Q2 2026, representing 17% year-over-year growth on an adjusted basis. Debut (trofinetide) Net Sales: $125 million in Q2 2026, up 30% year-over-year, driven almost ent…
Earnings Call Insights: ACADIA Pharmaceuticals (ACAD) Q2 2026 MANAGEMENT VIEW * CEO Catherine Owen Adams said ACADIA delivered total revenues of $308 million, driven by “strong commercial execution across both DAYBUE and NUPLAZID,” and hig…
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurri…
- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis - Increased…
Viatris VTRS, a global healthcare company, is scheduled to report second-quarter 2026 results on Aug. 6, before the opening bell. The Zacks Consensus Estimate for second-quarter revenues is pegged at $3.68 billion, while the same for earni…
Zoetis, Inc. ZTS is slated to report second-quarter results on Aug. 6, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $2.49 billion. The consensus mark for earnings is pin…
We expect Outlook Therapeutics OTLK to beat expectations when it reports third-quarter fiscal 2026 results later this month. In the last reported quarter, the company delivered a negative earnings surprise of 33.33%. The Zacks Consensus Es…
The dementia-related psychosis market is anticipated to increase during the forecast period (2026–2036), owing to the rising burden of dementia, the emergence of novel therapies such as ACP-204 (Remlifanserin) (Acadia Pharmaceuticals), Xan…
SAN DIEGO, July 30, 2026--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m.…